Komori
Sysmex (6869) · InitiativeFirst stated

Joint development of diagnostic agents using glycan markers

First written in FY2017. . Latest entry: FY2017.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Joint development of glycan-marker diagnostic drugs with AIST and GL-iA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2017First statedAnnual report

    「Our company, the National Institute of Advanced Industrial Science and Technology (AIST), and GL-i have been jointly developing new biomarkers for conditions including bile duct cancer. AIST is responsible for basic research such as marker discovery, GL-i for clinical research, and our company for the development of diagnostic reagents, obtaining regulatory approvals, manufacturing and sales, and we are promoting joint development toward commercialization.」

    It describes for the first time the joint development of diagnostic reagents using glycan markers, based on the division of roles among AIST and GL-i.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Sysmex yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Joint development of diagnostic agents using glycan markers | SYSMEX CORPORATION (6869) | Komori